co occurring addiction and less severe mental disorders
Download
Skip this Video
Download Presentation
Co-occurring Addiction and Less Severe Mental Disorders

Loading in 2 Seconds...

play fullscreen
1 / 98

Co-occurring Addiction and - PowerPoint PPT Presentation


  • 288 Views
  • Uploaded on

Co-occurring Addiction and Less Severe Mental Disorders. Richard Ries MD [email protected] Harborview Medical Center University of Washington Seattle, Wa. DUAL DIAGNOSIS IS:. TWO DIAGNOSES/ DISORDERS TWO SYSTEMS DOUBLE TROUBLE IN THE EYE OF THE BEHOLDER. MENTAL DISORDERS

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Co-occurring Addiction and ' - Angelica


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
co occurring addiction and less severe mental disorders

Co-occurring Addiction and Less Severe Mental Disorders

Richard Ries MD

[email protected]

Harborview Medical Center

University of Washington

Seattle, Wa

dual diagnosis is
DUAL DIAGNOSIS IS:
  • TWO DIAGNOSES/ DISORDERS
  • TWO SYSTEMS
  • DOUBLE TROUBLE
  • IN THE EYE OF THE BEHOLDER
examples of dual disorders
MENTAL DISORDERS

Schizophrenia

Bi-polar

Schizoaffective

Major Depression

Borderline Personality

Post Traumatic Stress

Social Phobia

others

ADDICTION DISORDERS

Alcohol Abuse/Depen.

Cocaine/ Amphet

Opiates

Marijuana

Polysubstance combinations

Prescription drugs

Examples of Dual Disorders:
dual disorders for everyone
Dual Disorders for Everyone?
  • If applied to all cases, Term has no meaning
    • (eg Spider phobia and “Running Addiction”)
  • Both Mental and Addiction Disorders need to be over threshold
  • Personality Disorders, other than Borderline not usually counted
  • Substance Induced Disorders cause diagnostic confusion
characteristics of the dual diagnosis client in king county ries 89
CHARACTERISTICS OF THE DUAL DIAGNOSIS CLIENT IN KING COUNTY… Ries ‘89

Severity of

Chemical Dependency

High

LH

HH

2

1

4

Severity of Psychiatric Low Condition

3

High

HL

LL

Low

systems problems
Systems Problems
  • Different Laws…commitment/confid.
  • Different funding..audits etc
  • Different personnel
  • Different training
  • Different certification
  • Different sites
  • Different Norms
the four quadrant framework for co occurring disorders
The Four Quadrant Framework for Co-Occurring Disorders

High severity

A four-quadrant conceptual framework to guide systems integration and resource allocation in treating individuals with co-occurring disorders (NASMHPD,NASADAD, 1998; NY State; Ries, 1993; SAMHSA Report to Congress, 2002)

Not intended to be used to classify individuals (SAMHSA, 2002), but  . . . 

Less severemental disorder/more severe substanceabuse disorder

More severemental disorder/more severe substanceabuse disorder

Less severemental disorder/less severe substanceabuse disorder

More severemental disorder/less severe substanceabuse disorder

Lowseverity

High severity

but what about non severely mentally ill co occurring pts
But what about NON- severely mentally ill co-occurring pts?
  • Like in Addiction Treatment settings
  • Like in Criminal Justice settings
  • Like in Primary Care Settings
  • Like in ER’s, especially with suicidal pts
  • The new TIP will bring more focus on these populations
likelihood of a suicide attempt
Risk Factor

Cocaine use

Major Depression

Alcohol use

Separation or Divorce

NIMH/NIDA

Increased Odds Of Attempting Suicide

62 times more likely

41 times more likely

8 times more likely

11 times more likely

ECA EVALUATION

Likelihood of a Suicide Attempt
double trouble relationship of alcohol drug problems to severe suicidality n 12 196
Double Trouble:RELATIONSHIP OF ALCOHOL & DRUG PROBLEMSTO SEVERE SUICIDALITY (n=12,196)

Percent With Severe Suicide Rating

ALCOHOL OR DRUG PROBLEMS

ODDS adjusted for age & gender

Walds = 235.41 p < .001

Ries & Russo unpub , 2003

drug induced psychopathology
Drug States

Withdrawal

Acute

Protracted

Intoxication

Chronic Use

Symptom Groups

Depression

Anxiety

Psychosis

Mania

Rounsaville ‘90

Drug Induced Psychopathology
slide13

Twelve-Month Prevalence of DSM-IV Independent Mood and Anxiety Disorders Among Respondents with DSM-IV Substance Use Disorders Who Sought Treatment in the Past 12 Months

Grant B, JAMA 2004

slide14

Twelve-Month Prevalence of DSM-IV Independent Mood and Anxiety Disorders Among Respondents with DSM-IV Substance Use Disorders Who Sought Treatment in the Past 12 Months

Grant B, JAMA 2004

comorbidity of depression and anxiety disorders
Comorbidity of Depression and Anxiety Disorders

50% to 65% of panic disorder patients have depression†

Panic

Disorder

70% of social anxiety

disorder patients have

depression

49% of social anxiety disorder patients have panic disorder**

HIGHLY COMMON…

HIGHLY COMORBID

Social Anxiety Disorder

Depression

67% of OCD patients have depression*

11% of social anxiety disorder patients have OCD**

OCD

diagnostic criteria for panic attack
Diagnostic Criteria for Panic Attack

A discreet period of intense fear or discomfort in which 4 or more of the following symptoms developed abruptly and reached a peak within 10 minutes:

  • Palpitations, pounding heart
  • Sweating
  • Trembling or shaking

Adapted with permission from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. 1994.

diagnostic criteria for panic attack continued
Dizziness

Chills or hot flushes

Feelings of unreality

Fear of losing control or going crazy

Fear of dying

Paresthesias

Choking feeling

Smothering or shortness of breath

Chest pain or discomfort

Abdominal distress

Diagnostic Criteria for Panic Attack Continued
somatic symptoms in panic disorder
Somatic Symptoms In Panic Disorder

Gastro-intestinal Symptoms

Chest Pain

SOMATIC SYMPTOMS

Headache

Dizziness

Fatigue

quality of life in panic disorder
Quality of Life in Panic Disorder

%

Marital Discord

(past 2 weeks)

Use Of ER

(past year)

Financial Dependence

(welfare or disability)

Markowitz et al. Arch Gen Psychiatry. 1989;46:984.

dsm iv diagnostic criteria for ptsd
DSM-IV Diagnostic Criteria for PTSD
  • Exposure to a traumatic event in which the person:
    • experienced, witnessed, or was confronted by death or serious injury to self or others

AND

    • responded with intense fear, helplessness, or horror

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. 1994.

dsm iv diagnostic criteria for ptsd continued
DSM-IV Diagnostic Criteria for PTSD Continued
  • Symptoms
    • appear in 3 symptom clusters: re-experiencing, avoidance/numbing, hyperarousal
    • last for > 1 month
    • cause clinically significant distress or impairment in functioning
dsm iv diagnostic criteria for ptsd re experiencing
DSM-IV Diagnostic Criteria for PTSD Re-experiencing
  • Persistent re-experiencing of  1 of the following:
    • recurrent distressing recollections of event
    • recurrent distressing dreams of event
    • acting or feeling event was recurring
    • psychological distress at cues resembling event
    • physiological reactivity to cues resembling event
dsm iv diagnostic criteria for ptsd avoidance numbing
DSM-IV Diagnostic Criteria for PTSD Avoidance/Numbing
  • Avoidance of stimuli and numbing of general responsiveness indicated by  3 of the following:
    • avoid thoughts, feelings, or conversations*
    • avoid activities, places, or people*
    • inability to recall part of trauma
    •  interest in activities
    • estrangement from others
    • restricted range of affect
    • sense of foreshortened future
dsm iv diagnostic criteria for ptsd hyperarousal
DSM-IV Diagnostic Criteria for PTSD Hyperarousal
  • Persistent symptoms of increased arousal  2:
    • difficulty sleeping
    • irritability or outbursts of anger
    • difficulty concentrating
    • hypervigilance
    • exaggerated startle response

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. 1994.

slide25

Prevalence of Trauma and Probability of PTSD

1

Threat w/

Weapon

Physical

Attack

Molestation

Witness

Accident

Combat

Rape

2

1

2

impaired quality of life with ptsd
Impaired Quality of Life with PTSD

SF-36 Score

SF-36 = 36 item short form health survey

Lower score = more impairment

Malik M et al. J Trauma Stress. 1999;12:387-393.

common somatic complaints of social anxiety disorder
Common Somatic Complaints Of Social Anxiety Disorder

Stuttering

Blushing

Palpitations

Sweating

Trembling

And Shaking

“Butterflies”

Beidel. J Clin Psychiatry. 1998;59(suppl 17):27.

social anxiety disorder spin screener
Social Anxiety DisorderSPIN Screener
  • Is being embarrassed or looking stupid among your worst fears?
  • Does fear of embarrassment cause you to avoid doing things or speaking to others?
  • Do you avoid activities in which you are the center of attention?

Katzelnick et al. Presented at 37th Annual Meeting of the American College of Neuropsychopharmacology; December 14-18, 1998; Los Croabas, Puerto Rico.

social anxiety disorder educational and occupational impairment
Social Anxiety Disorder: Educational and Occupational Impairment

0.0

-5.0

Impairment**(%)

-10.0

 Wages

 CollegeGraduation

-15.0

 ProfessionalOr Management Positions

-20.0

* LSAS score in controls = 25; ** Impairment (%) refers to percentage change in wages and percentage point changes in probabilities of college graduation and having a technical, professional, or managerial job.

Katzelnick et al. Presented at 37th Annual Meeting of the American College of Neuropsychopharmacology;

December 14-18, 1998; Los Croabas, Puerto Rico.

therapy plan
Psych

Bio Labs

Meds (anti-depressants, etc.)

Psych psychotherapy education groups

process groups

Social Couples conf.

D/C planning

housing, etc.

CD

Labs

Meds (withdrawal, craving, etc.)

Step work

Groups

AA Meetings

Intervention

Sober housing

Therapy Plan
slide31

Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.Nunes EV, Levin FR.

DATA SYNTHESIS: For the HDS score, the pooled effect size from the random-effects model was 0.38 (95% confidence interval, 0.18-0.58). Heterogeneity of effect on HDS across studies was significant (P <.02), and studies with low placebo response showed larger effects.

Moderator analysis suggested that diagnostic methods and concurrent psychosocial interventions influenced outcome.

Studies with larger depression effect sizes (>0.5) demonstrated favorable effects of medication on measures of quantity of substance use, but rates of sustained abstinence were low.

CONCLUSIONS: Antidepressant medication exerts a modest beneficial effect for patients with combined depressive- and substance-use disorders. It is not a stand-alone treatment, and concurrent therapy directly targeting the addiction is also indicated.

More research is needed to understand variations in the strength of the effect, but the data suggest that care be exercised in the diagnosis of depression-either by observing depression to persist during at least a brief period of abstinence or through efforts by clinical history to screen out substance-related depressive symptoms.

slide32

Fluoxetine versus placebo in depressed alcoholic cocaine abusers.Cornelius JR, Salloum IM, Thase ME, Haskett RF, Daley DC, Jones-Barlock A, Upsher C, Perel JM.

All 51 patients participated in a double-blind, parallel group study of fluoxetine versus placebo in depressed alcoholics. The principal focus of this article is the one-third of the depressed alcoholics who also abused cocaine and how the treatment response of those 17 patients compared with that of the 34 depressed alcoholics who did not abuse cocaine.

During the study, no significant difference in treatment outcome was noted between the fluoxetine group (N = 8) and the placebo group (N = 9) for cocaine use, alcohol use, or depressive symptoms. In addition, no significant within-group improvement was noted for any of these outcome variables in either of the two treatment groups.

Indeed, across the combined sample of 17 depressed alcoholic cocaine abusers, the mean Beck Depression Inventory (BDI) score worsened slightly from 19 to 21 during the course of the study, and 71 percent of the patients continued to complain of suicidal ideations at the end of the study.

The 17 cocaine-abusing depressed alcoholics showed a significantly worse outcome than the 34 non-cocaine abusing depressed alcoholics on the 24-item Hamilton Rating Scale for Depression (HAM-D) and BDI depression scales and on multiple measures of alcohol consumption. These findings suggest that comorbid cocaine abuse acts as a robust predictor of poor outcome for the drinking and the depressive symptoms of depressed alcoholics.

slide33

Paroxetine for social anxiety and alcohol use in dual-diagnosed patients.Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, Brady KT, Davidson JR.Fifteen individuals meeting DSM-IV criteria for both social anxiety disorder and alcohol use disorder were randomized to treatment. Paroxetine (n = 6) or placebo (n = 9) was given in a double-blind format for 8 weeks using a flexible dosing schedule. Dosing began at 20 mg/d and increased to a target dose of 60 mg/d.

  • There was a significant effect of treatment group on social anxiety symptoms, where patients treated with paroxetine improved more than those treated with placebo on both the Clinical Global Index (CGI) and the Liebowitz Social Anxiety Scale (Ps < or = 0.05).
  • On alcohol use, there was not a significant effect of treatment on quantity/frequency measures of drinking, but there was for the CGI ratings (50% paroxetine patients versus 11% placebo patients were improvers on drinking, P < or = 0.05).
  • This pilot study suggests that paroxetine is an effective treatment for social anxiety disorder in individuals with comorbid alcohol problems, and positive treatment effects can be seen in as little as 8 weeks. Further study is warranted to investigate its utility in helping affected individuals reduce alcohol use. Copyright 2001 Wiley-Liss, Inc.
why aren t antidepressants more effective in addictions patients
Why aren’t Antidepressants more effective in addictions patients?
  • Psychiatric outcomes:
    • Antidepressants only beat placebo by 20% anyway in NON addicts
    • Study patients also get “addiction rx”
    • Maybe addiction rx is more anti-dep, anti anx than we think…viz Schuckit 80% -> 20%
    • This is poorly studied…maybe better with 12 step
    • Sub Induced criteria are wrong
  • Addictions outcomes
    • Meds take focus off sobriety
    • Meds reinforce sobriety
    • Just don’t work for this
slide35

Concurrent alcoholism and social anxiety disorder: a first step toward developing effective treatments.Randall CL, Thomas S, Thevos AK.The present study investigated whether simultaneous treatment of social phobia and alcoholism, compared with treatment of alcoholism alone, improved alcohol use and social anxiety for clients with dual diagnoses of social anxiety disorder and alcohol dependence.

  • METHODS: The design was a two-group, randomized clinical trial that used 12 weeks of individual cognitive behavioral therapy for alcoholism only (n = 44) or concurrent treatment for both alcohol and social anxiety problems (n = 49). Outcome data were collected at the end of 12 weeks of treatment and at 3 months after the end of treatment.
  • RESULTS: Results with intent-to-treat analyses showed that both groups improved on alcohol-related outcomes and social anxiety after treatment.
  • Counter to the hypothesis, the group treated for both alcohol and social anxiety problems had worse outcomes on three of the four alcohol use indices.
  • No treatment group effects were observed on social anxiety indices.
  • CONCLUSIONS: Implications for the staging of treatments for coexisting social phobia and alcoholism are discussed, as well as ways that modality of treatments might impact outcomes.
slide36

A cognitive-behavioral treatment for incarcerated women with substance abuse disorder and posttraumatic stress disorder: findings from a pilot study.Zlotnick C, Najavits LM, Rohsenow DJ, Johnson DM.This preliminary study evaluates the initial efficacy of a cognitive-behavioral treatment, Seeking Safety, as an adjunct to treatment-as-usual in an uncontrolled pilot study of incarcerated women with current SUD and comorbid PTSD.

  • Of the 17 incarcerated women with PTSD and SUD who received Seeking Safety treatment and had outcome data,
  • results show that nine (53%) no longer met criteria for PTSD at the end of treatment; at a followup 3 months later, seven (46%) still no longer met criteria for PTSD
  • Additionally, there was a significant decrease in PTSD symptoms from intake to posttreatment, which was maintained at the 3-month followup assessment.
  • Based on results from a diagnostic interview and results of urinalyses, six (35%) of the women reported the use of illegal substances within 3 months from release from prison. Measures of client satisfaction with treatment were high. Recidivism rate (return to prison) was 33% at a 3-month followup.
slide37

Can encouraging substance abuse patients to participate in self-help groups reduce demand for health care? A quasi-experimental studyn=1774, 1 year follow-upHumphreys et al ..2001

Outpt Inpt days Abstinence

Visits Rates

  • 12 Step 13.1 10.5 45.7
  • Cog Beh 17 17 36.2

* all p< .001 ** 64% higher cost for CBT

dual screening
Dual Screening:
  • the “Dual Cage”…………….easy, but no data
  • ASAM pt placement………..needs experience, little or no data
  • ASI psych…………………….short, available, good screening, good data
  • Beck, Zung, Ham D etc…..easy, good data, may be limited
  • Brief Symptom Inventory…easy, broad symptom mix
  • Others……………………………see new Co-occurring TIP in 12-04
dual cage questions
“Dual CAGE” QUESTIONS
  • Cut Down (or stopped)
    • Because mental symptoms worsened
    • Because MH doctor or therapist suggested
  • Annoyed when drug/alc. use discussed
    • Annoyed, anxious or angry,… fights when using
    • Admitted to ER or hospital for psych when using or not
    • ADHD when child
  • Guilty about use
    • Guilty, depressed, suicidal when using or not
    • Ever made a suicide attempt when using or not
cage questions
CAGE Questions
  • Eye opener: taken drink or drug in AM to feel better
    • Taken a drink or drug to blot out symptoms
    • Taken drink or drug with psych med
    • Not taken meds because of using drug/alc (forgot, avoid mixing, etc.)
  • What are 2 or 3 reasons you use alc/drugs?
  • What are 2 or 3 reasons you might want to stop or cut down?
medications
Medications
  • Essential to Treatment of Severely Mentally Ill
    • Substance Use and Not-Taking Meds are the 2 top reasons for De-Comp
    • Should be part of court orders
    • Monitored by Case managers, nurses, doctors
  • For Dep/Anx, less clear
    • Personal experience shows maximizing 12 step AND use of meds is best rx
it may not be that the med s stopped working but
It may not be that the med(s) stopped working, but……
  • The patient stopped the med
  • The patient stopped the med AND used drugs and/or alcohol…...
  • OR lowered the med and used…
  • OR used on top of the med….
  • OR used twice the dose on one day and nothing the next….
  • Stimulants ( cocaine/amphets) are most MSE destructive.
how to use aa as a treatment partner
How to use AA as a treatment partner
  • 1. Know something about AA, its history, presence in your community, structure and content
  • 2. Helpful Readings:
    • Brown: A psychological view of the 12 steps
    • AA: AA for the medical practitioner; and
    • The AA member and medications
    • Twelve Step Facilitation Therapy Manual-
      • Project Match, NIAAA web site
    • Forman: “One AA Meting doesn’t fit all”
slide44

One year ABSTINENCE was predicted by:

    • AA involvement (OR=2.9), ( n=377)
    • not having pro-drinking influences in one\'s network (OR=0.7
    • having support for reducing consumption from people met in AA (versus no support; OR=3.4).
    • In contrast, having support from non-AA members was not a significant predictor of abstinence.
          • Kaskutas: Addiction 2002
double trouble recovery dtr outcomes
Double Trouble Recovery (DTR) Outcomes
  • Members of 24 DTR groups (n=240) New York City, 1 year outcomes
  • Drug/alcohol abstinence = 54% at baseline, increased to 72% at follow-up.
  • More attendance = better Medication adherence,
  • Better Medication adherence = less hospitalization
    • Magura Add Beh 2003, Psych Serv 2002
dual dep anx rx plan
Dual Dep/Anx RX plan
  • Differential Dx
  • 12 step facilitation
  • Meds if indicated ( and I often use them)
  • Visits:
    • Ries 1/week ( 12 step facil and meds)
    • AA 3x week or 90 in 90
    • Meet with sponsor
    • Meet with family
low mental illness high addictions outpt gets
Low mental illness/High addictions outpt gets
  • In most MHC’s:
    • MD visit q 3 months
    • CM visit q 2 wks…focus on ADL’s
    • Maybe dual dx group 1-2 hrs/wk
    • Limited expectations of recovery
    • Pschotherapy time ~ 0-2 hrs week
  • In the most Addictions IOP’s
    • MD visit 1/ 3 months, often 1’ care
    • CM 1:1 q 2 wks….focus on Sub use, U tox’s
    • IOP group 3 hrs-3x week
    • Expectations of Sobriety/progress
    • Psychotherapy time 3-10 hrs week ( plus more AA)
slide48

Report Questions Ability of National Treatment Infrastructure to Deliver Quality Care

SOURCE: Adapted by CESAR from the McLellan, A. T., Carise, D., and Kleber, J., “Can the National Addiction Treatment Infrastructure Support the Public’s Demand for Quality Care?” Journal of Substance Abuse Treatment 25(2):117-121, 2003. For more information, contact Dr. A. Thomas McLellan at [email protected]

301-405-9770 (voice) 301-403-8342 (fax) [email protected] www.cesar.umd.edu 

CESAR FAX is supported by VOIT 1996-1002, awarded by the U.S. Department of Justice through the Governor’s Office of Crime Control and Prevention. CESAR FAX may be copied without permission. Please cite CESAR as the source.

medication monitoring and motivating
Medication monitoring and motivating
  • Know who is on what and what for
  • Know the prescriber if possible
    • Sit in on med sessions onsite
    • Talk to off-site doctor or nurse PRE problem!!!
  • Know something about meds…
    • ATTC Tech transfer centers summary
    • New COD TIP ( Dec 04)
    • NIMH web site, NAMI web site
medications counselor s role
Medications: counselor’s role
  • Ask the pt about :
    • Compliance…
      • “sometimes people forget their medications…how often does this happen to you?” …ie % not taking
    • Effectiveness…
      • “how well do you think the meds are working?…
      • what do you notice…
      • here is what I notice
    • Side Effects….
      • “ are you having any side effects to the medication?…
      • what are they…
      • have you told the prescriber?
      • do you need help with talking to the presciber?
medications potential problems
Medications….potential problems
  • Can reinforce addiction denial if recovery is not integrated and supported…esp by the prescriber..( so work with them)
  • Can be expensive, cause side effects, could be used in overdose.
  • Encumber the pt with seeing MD, or mental health system, cost, convenience etc….ie make sure they are really necessary.
  • Active participation in recovery can be both antidep and antianx…but if these problems continue, or disrupt recovery, meds should be considered
slide54

A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder.Guardia J, Segura L, Gonzalvo B, Iglesias L, Roncero C, Cardus M, Casas M.METHODS: A total of 60 alcohol-dependent patients were assigned to 12 weeks\' treatment with either olanzapine or placebo. The primary variable relapse to heavy drinking rate was evaluated by means of intention-to-treat analyses. Alcohol consumption, craving, adverse events, and changes in the biochemical markers of heavy drinking and possible toxicity were also evaluated.

  • RESULTS: We did not find significant differences in the survival analysis between placebo and olanzapine-treated patients (Kaplan-Meier log rank = 0.46, df = 1, p = 0.50). Eleven (37.9%) patients treated with olanzapine relapsed compared with 9 (29%) of those receiving placebo (chi = 0.53, df = 1, p = 0.5). Although some adverse events (weight gain, increased appetite, drowsiness, constipation, and dry mouth) were found more frequently in the olanzapine group, differences did not reach statistical significance in comparison with the placebo group.
  • CONCLUSIONS: We found no differences in relapse rate or other drinking variables when comparing olanzapine with placebo-treated patients.
slide55

Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey.Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI.. The authors report data from a retrospective survey of substance use in 58 patients treated with clozapine who had a history of comorbid schizophrenia (or schizoaffective disorder) and substance use disorder. Of these 58 patients, 43 were being treated with clozapine at the time of the survey; the remaining 15 patients had discontinued clozapine before the survey.

  • More than 85% of the patients who were active substance users at the time of initiation of treatment with clozapine decreased their substance use over the course of clozapine administration. For patients who continued treatment with clozapine up to the present, the decrease in substance use was strongly correlated with a decrease in global clinical symptoms.
slide56

First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group.

  • METHODS: The study involved 262 patients. Patients with a history of substance dependence within 1 month prior to entry were excluded.
  • RESULTS: Of this sample, 97 (37%) had a lifetime diagnosis of substance use disorder (SUD); of these 74 (28% of the total) had a lifetime cannabis use disorder (CUD) and 54 (21%) had a lifetime diagnosis of alcohol use disorder (AUD).
    • Those with CUD had a lower age of onset than those without.
    • Patients with SUD were more likely to be men.
    • Patients with SUD had more positive symptoms and fewer negative symptoms than those without SUD, and they had a longer duration of untreated psychosis.
    • The 12-week response data indicated that 27% of patients with SUD were responders compared to 35% of those without SUD.
    • Patients with AUD were less likely to respond to olanzapine than those without AUD.
  • DISCUSSION: These data suggest that first-episode patients are quite likely to have comorbid substance use disorders, and that the presence of these disorders may negatively influence response to antipsychotic medications, both typical and atypical antipsychotics, over the first 12 weeks of treatment.
slide57

Quetiapine in bipolar disorder and cocaine dependence.Brown ES, Nejtek VA, Perantie DC, Bobadilla L. METHODS: Open-label, add-on, quetiapine therapy was examined for 12 weeks in 17 outpatients with bipolar disorder and cocaine dependence. Subjects were evaluated with a structured clinical interview; Hamilton Depression Rating (HDRS), Young Mania Rating (YMRS), Brief Psychiatric Rating (BPRS) scales; and Cocaine Craving Questionnaire (CCQ). Urine samples and self-reported drug use were also obtained. Data were analyzed using a last observation carried forward method on all subjects given medication at baseline.

  • RESULTS:
  • Significant improvement from baseline to exit was observed in HDRS, YMRS, BPRS and CCQ scores (p < or = 0.05).
  • Dollars spent on cocaine and days/week of cocaine use decreased non-significantly, and urine drug screens did not change significantly from baseline to exit.
  • Quetiapine was well tolerated, with no subjects to our knowledge discontinuing because of side-effects. CONCLUSIONS: The use of quetiapine was associated with substantial improvement in psychiatric symptoms and cocaine cravings. The findings are promising and suggest larger controlled trials of quetiapine are needed in this population.
slide58

Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone.Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD.METHOD: This study involved retrospective assessment of abstinence (cessation of alcohol and cannabis use) in 41 patients treated with either risperidone (n=8) or clozapine (n=33) for at least 1 year. In 32 of these 41 patients, information was available on whether abstinence occurred during the 1-year period.

  • RESULTS: Abstinence rates were significantly higher in patients treated with clozapine than in those treated with risperidone (54% vs. 13%, p=0.05).
slide59

Risperidone reduces limited access alcohol drinking in alcohol-preferring rats.Ingman K, Honkanen A, Hyytia P, Huttunen MO, Korpi ER.Department of Pharmacology and Clinical Pharmacology, University of Turku, Itainen Pitkakatu 4, FIN-20520, Turku, FinlandAn atypical antipsychotic drug risperidone reduced ethanol drinking of ethanol-preferring Alko, Alcohol (AA) rats in a limited access paradigm. Its effect was transient at a dose known to preferentially antagonize the 5-HT(2) receptors (0.1 mg/kg, s.c.), but long-lasting when the dose was increased to 1.0 mg/kg that also blocks dopamine D(2) receptors.

slide60

Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence.Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D.OBJECTIVE: To examine the efficacy of atypical neuroleptics for decreasing craving and drug relapses during protracted withdrawal in individuals dually diagnosed with schizophrenia and cocaine dependence. METHOD: We conducted a 6-week, open-label pilot study comparing risperidone with typical neuroleptics in a sample of withdrawn cocaine-dependent schizophrenia patients.

  • RESULTS: Preliminary results suggest that individuals treated with risperidone had significantly less cue-elicited craving and substance abuse relapses at study completion. Further, they showed a trend toward a greater reduction in negative and global symptoms of schizophrenia.
  • CONCLUSION: Atypical neuroleptics may help reduce craving and relapses in this population. Future research should include more rigorous double-blind placebo-controlled studies with this class of medications.
comorbid substance abuse associated with noncompliance in schizophrenia

P < 0.05

Comorbid Substance Abuse Associated With Noncompliance in Schizophrenia
  • Nearly half of all patients in a prospective 4-year study (N = 99) were active substance abusers (n = 42)
  • Patients who actively abused substances were significantly more likely to be noncompliant

% Noncompliant

Hunt GE et al. Schizophrenia Res. 2002;54:253-264.

it may not be that the med s stopped working but62
It may not be that the med(s) stopped working, but……
  • The patient stopped the med
  • The patient stopped the med AND used drugs and/or alcohol…...
  • OR lowered the med and used…
  • OR used on top of the med….
  • OR used twice the dose on one day and nothing the next….
  • Stimulants ( cocaine/amphets) are most MSE destructive.
risperdal consta injection kit components

SmartSite® Access Device

Aqueous Diluent

Risperidone Microspheres

Assembled

RISPERDAL® CONSTA™

RISPERDAL® CONSTA™Injection Kit Components

Needle Pro® DeviceSafety Needle

PRC approved with changes: 11/10/03 (RISPERDAL CONSTA Promotional slide kit)

blood levels over time after single dose

0

1

2

3

4

5

6

7

8

9

10

11

12

Blood Levels Over Time After Single Dose*

PRC approved with changes: 11/10/03 (RISPERDAL CONSTA Promotional slide kit)

Risperidone +9-hydroxyrisperidone (ng/mL)

Time (wk)

Antipsychotic Supplementation

*25-mg dose, N = 14.Data on file, Janssen Pharmaceutica Products, L.P.

substance induced psychoses
Substance Induced Psychoses
  • Amphet/Methamphetamines
  • Cocaine
  • Ecstacy
  • Hallucinogens ( strong THC too)
  • Other Rave Drugs
  • Alcohol WD and Hallucinosis
comparing the known efficacy of antiepileptic agents in bipolar disorder
COMPARING THE KNOWN EFFICACY OF ANTIEPILEPTIC AGENTS IN BIPOLAR DISORDER

Keck & McElroy, 2002

comparing the known efficacy of antiepileptic agents in bipolar disorder68
COMPARING THE KNOWN EFFICACY OF ANTIEPILEPTIC AGENTS IN BIPOLAR DISORDER

Keck & McElroy, 2002

slide69

How real are patients in placebo-controlled studies of acute manic episode?Storosum JG, Fouwels A, Gispen-de Wied CC, Wohlfarth T, van Zwieten BJ, van den Brink W.OBJECTIVE: To determine whether the results from placebo-controlled studies conducted in patients with manic episode can be generalised to a routine population of hospitalised acute manic patients.

  • METHODS: A list of four most prevalent inclusion and the nine most prevalent exclusion criteria was constructed for participation in previous randomised-controlled trials (RCTs). On the basis of this list, a consecutive series of 68 patients with 74 episodes of acute mania who had been referred for routine treatment were retrospectively assessed to determine their eligibility for a hypothetical but representative randomised controlled trial.
  • RESULTS: Only 16% of the manic episodes would qualify for the hypothetical trial (male episodes 28%, female episodes 10%),
  • ….whereas 37%, 20% and 27% of the manic episodes would have to be excluded because they did no fulfil one, two or at least three of the inclusion or exclusion criteria. CONCLUSION: Only a small percentage acute manic episodes in a routine mental hospital seem to qualify for a standard placebo-controlled RCT.. These notions should be taken into account when evaluating the results of RCTs in bipolar patients with an acute manic episode.
slide70

The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification.Malcolm R, Myrick H, Roberts J, Wang W, Anton RF.A double-blind, randomized controlled trial of patients (n = 136) meeting DSM-IV criteria for alcohol withdrawal and stratified based on detoxification history were treated with carbamazepine or lorazepam for 5 days on a fixed dose tapering schedule. Mood symptoms improved for all subjects regardless of medication or detoxification history.

  • main effect favoring carbamazepine in reducing anxiety (p = 0.0007).
  • main effect of medication on sleep that again favored carbamazepine (p = 0.0186).
  • In this study of outpatients with mild to moderate alcohol withdrawal, carbamazepine was superior to lorazepam in reducing anxiety and improving sleep.
slide71

Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL.Veterans Affairs Puget Sound Health Care System and Department of Psychiatry, University of Washington School of Medicine, Seattle, Washington 98108, USA. [email protected]

slide72

Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.Citrome L, Levine J, Allingham B.METHODS: For each calendar year from 1994 through 1998, data were drawn from a database containing clinical and drug prescription information for every inpatient in the adult civil facilities of the New York State Office of Mental Health.

  • RESULTS: In 1994 a total of 26.2 percent of inpatients diagnosed as having schizophrenia received a mood stabilizer, compared with 43.4 percent in 1998. In 1994 lithium was the most commonly prescribed mood stabilizer, for 13.2 percent of patients, followed by valproate, for 12.3 percent. In 1998 valproate was the most commonly prescribed, for 35 percent of patients, followed by lithium, for 11.3 percent. On average, patients received valproate for about two-thirds of their hospital stay, at a mean dose of 1,520 mg per day.
  • CONCLUSIONS: The adjunctive use of valproate nearly tripled from 1994 to 1998 among patients with a diagnosis of schizophrenia. Valproate has become the most commonly prescribed mood stabilizer for this population, despite the paucity of evidence in the literature for efficacy in this use. Controlled clinical trials are needed to examine the adjunctive use of mood stabilizers, in particular valproate, among patients with schizophrenia.
slide73

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA.METHODS: A total of 249 inpatients with schizophrenia were randomly assigned,

  • RESULTS: Combination treatment with risperidone or olanzapine plus divalproex was associated with different scores on the hostility item of the PANSS compared with antipsychotic monotherapy.
  • This result was not seen beyond the first week of treatment, but there was a trend toward a difference in effect for the entire treatment period.
  • Combination therapy had a significantly greater antihostility effect at days 3 and 7 than monotherapy.
  • The effect on hostility appears to be statistically independent of antipsychotic effect on other PANSS items reflecting delusional thinking, a formal thought disorder, or hallucinations.
  • CONCLUSIONS: Divalproex sodium may be useful as an adjunctive agent in specifically reducing hostility in the first week of treatment with risperidone or olanzapine among patients with schizophrenia experiencing an acute psychotic episode.
slide74

Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications.Wassef AA, Hafiz NG, Hampton D, Molloy M.Divalproex sodium has been approved for use in treating bipolar disorder. Its usefulness in schizophrenia has yet to be adequately assessed.

  • Compared with those who received no or delayed augmentation, the early-augmentation group required 44.8% fewer inpatient days from the initiation of haloperidol treatment. Patient response to treatment was particularly noted in suspiciousness, hallucinations, unusual thought content, and emotional withdrawal.
  • Early augmentation with valproate may reduce the length of inpatient stays and provide substantially better therapeutic outcomes. It is, however, premature to recommend changes in the standard clinical management of schizophrenia on the basis of the data provided herein, in view of the small sample and open-label nature of the report.
slide75

Depakote with Atypical Antipsychotic: lipids

  • Patients treated with a combination of Depakote and Zyprexa experienced a minimal increase in total cholesterol compared to the greater increase in patients treated with Zyprexa when used as monotherapy:
      • +26.62 mg/dL for Zyprexa monotherapy (baseline: 193 mg/dL).
      • +0.87 mg/dL for Depakote plus Zyprexa (baseline: 198 mg/dL).
  • Patients treated with a combination of Depakote and Risperdal experienced a decrease in total cholesterol compared to Risperdal when used as monotherapy:
      • +9.64 mg/dL for Risperdal monotherapy (baseline: 188 mg/dL).
      • -13.44 mg/dL for Depakote plus Risperdal (baseline: 192 mg/dL).
  • Patients in the Zyprexa monotherapy group had the highest rate of shift from a normal total cholesterol (<200 mg/dL) to a high total cholesterol (>200 mg/dL).
  • Casey et al APA conv 2004
slide76

Lancet. 2003 May 17;361(9370):1677-85.

  • Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Johnson BA et al
  • METHODS: double-blind randomised controlled 12-week clinical trial comparing oral topiramate and placebo for treatment of 150 individuals with alcohol dependence..
  • FINDINGS: At study end, participants on topiramate, compared with those on placebo, had
  • 2.88 (95% CI -4.50 to -1.27) fewer drinks per day (p=0.0006),
  • 3.10 (-4.88 to -1.31) fewer drinks per drinking day (p=0.0009),
  • 27.6% fewer heavy drinking days (p=0.0003),
  • 26.2% more days abstinent (p=0.0003), and a
  • log plasma gamma-glutamyl transferase ratio of 0.07 (-0.11 to - 0.02) less (p=0.0046).
  • Topiramate-induced differences in craving were also significantly greater than those of placebo, of similar magnitude to the self-reported drinking changes, and highly correlated with them.
slide77

Topiramate for Alcohol Withdrawal:

1: Med Arh. 2002;56(4):211-2.

A pilot study of Topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Rustembegovic A, Sofic E, Kroyer G. Anton Proksch Institute, Vienna, Austria.

12 patients with median age of 49.5 years and median body weight of 76.3 kg were treated with topiramate twice daily for up 30 days, starting with a dose of 50 mg in the morning and 50 mg in the evening.

The preliminary findings of this study suggest that topiramate is very effective against tonic-clonic seizures in alcohol withdrawal syndrome. No side effects were observed. Only two patients had loss of body weight (3-3.5 kg/4 weeks).

slide78

J Clin Psychopharmacol. 2004 Aug;24(4):374-8. Vieta E,et al

  • Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.
  • Twenty-six Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition bipolar spectrum patients received olanzapine plus topiramate cotherapy for treatment of their manic (n = 14), hypomanic (n = 6), depressive (n = 2), and mixed (n = 1) symptoms for 1 year. Three rapid cycling patients were also enrolled despite being euthymic. Thirteen (50%) patients completed the 1-year follow-up.
  • By intent-to-treat, patients significantly improved from baseline in
  • Young Mania Rating Scale scores (P < 0.0001),
  • Hamilton Depression Rating Scale (P < 0.05), and
  • Modified Clinical Global Impressions for Bip (mania P < 0.0001,
  • Depression ( Ham) P < 0.05, ………overall P < 0.0001).
  • Most patients gained weight during the first month of combined treatment (mean weight gain 0.7 +/- 0.6 kg), but at the 12-month endpoint, the mean weight change was -0.5 +/- 1.1 kg.
slide79

Gabapentin for the treatment of ethanol withdrawal.Voris J, Smith NL, Rao SM, Thorne DL, Flowers QJ.We retrospectively report on the use of gabapentin for ethanol withdrawal in 49 patients. Thirty-one patients were treated in the outpatient program and 18 in the general inpatient psychiatric unit.

  • Positive outcomes as evidenced by completion of gabapentin therapy were achieved in 25 out of 31 outpatients and 17 out of 18 inpatients.
  • Statistical significance was reached regarding the positive relationship between prior ethanol use and inpatient "as needed" benzodiazepine use. Both sets of data suggest that gabapentin works well for the mild to moderate alcohol withdrawal patient.
slide80

Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients.Karam-Hage M, Brower KJ.Alcohol-dependent outpatients with persisting insomnia were treated with either gabapentin or trazodone. Patients were assessed at baseline and after 4-6 weeks on medication using the Sleep Problems Questionnaire (SPQ). Of 55 cases initially treated, 9% dropped out due to morning drowsiness. Of the remaining 50 cases, 34 were treated with gabapentin (mean dose +/- SD = 888 +/- 418 mg) at bedtime and 16 were treated with trazodone (105 +/- 57 mg) at bedtime.

  • Both groups improved significantly on the SPQ but the gabapentin group improved significantly more than the trazodone group. Controlled studies are warranted to replicate these findings.
slide81

A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome.Rustembegovic A, Sofic E, Tahirovic I, Kundurovic Z.In this study for thirty (30) patients with alcohol withdrawal syndrome, the response to anticolvusant gabapentin was assessed. Thirty (30) patients with median age of 57.0 years and median body weight of 79.1 kg were treated with gabapentin 3 x 300 mg daily for up 30 days.

  • The preliminary findings of this study suggest that gabapentin is very effective against tonic-clonic seizures in alcohol withdrawal syndrome.
  • Gabapentin was safe and well tolerated. For twenty (20) patients no side effect were observed.
slide82

Lamotrigine in patients with bipolar disorder and cocaine dependence.Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla L. METHOD: Lamotrigine was started at a dose of 25 mg/day (12.5 mg/day in those taking valproic acid) and titrated to a maximum dose of 300 mg/day. The subjects consisted of 13 men and 17 women with cocaine dependence and bipolar I disorder (N = 22), bipolar II disorder (N = 7), or bipolar disorder not otherwise specified (N = 1), with a mean +/- SD age of 35.4 +/- 7.2 years. Data were analyzed using the last observation carried forward on all subjects who completed the baseline evaluation and at least 1 postbaseline assessment.

  • RESULTS: Significant improvement was observed in HAM-D, YMRS, and BPRS scores
  • (p < or =.02). Cravings also significantly decreased as measured by the CCQ (p <.001). Dollar amount spent on drugs decreased nonsignificantly. Lamotrigine was well tolerated, with no subjects discontinuing due to side effects.
  • CONCLUSION: Lamotrigine treatment was well tolerated in this sample and associated with statistically significant improvement in mood and drug cravings but not drug use. The findings suggest that larger controlled trials of lamotrigine are needed in this population.
anti opiate addiction meds
Anti-opiate Addiction Meds
  • Harm reduction:..opiates
    • Methadone
      • Only through Methadone agencies for Addiction
      • Confusion when injury/pain/addiction co-occurr
    • LAAM.
      • Due to liver prolems ( minor) is being phased out
    • Buprenorphine
      • Not given orally
    • Suboxone
      • Combination of Bup plus Naloxone subligual
      • Absorb the Bup, not the Naloxone
      • If used IV then immediate Withdrawal from naloxone
      • Practitioners need special DEA # and training
  • Withdrawal treatment
    • Methadone
    • Buprenorphine
    • Clonidine ++
slide84

Intrinsic Activity: Full Agonist (Methadone), Partial Agonist (Buprenorphine), Antagonist (Naloxone)

100

90

Full Agonist

(Methadone)

80

70

Intrinsic Activity

60

Partial Agonist

50

(Buprenorphine)

40

30

20

10

Antagonist (Naloxone)

0

-10

-9

-8

-7

-6

-5

-4

Log Dose of Opioid

slide85

Figure 3: Induction for Patient Physically Dependent

On Short-acting Opioids, Day 1

Patient dependent on short-acting opioids?

Yes

Stop;

not dependent

on short-acting

opioids

Withdrawal symptoms

present 12-24 hrs

after last use of opioids?

No

Yes

Give buprenorphine

2-4 mg, observe 2+ hrs

Daily dose established.

GO TO SWITCH

DIAGRAM (Fig. 6)

No

No

Withdrawal symptoms

return?

Withdrawal symptoms

continue or return?

Yes

Yes

Repeat dose up to

maximum 8 mg for first day

No

Manage withdrawal

symptomatically

Withdrawal symptoms

relieved?

Yes

Daily dose established.

GO TO SWITCH

DIAGRAM (Fig. 6)

Return next day for

continued induction.

GO TO INDUCTION DAY 2

DIAGRAM (Fig. 5)

slide86

Drug Interactions with Buprenorphine

Benzodiazepines and other sedating drugs

Medications metabolized by cytochrome P450 3A4

Opioid antagonists

Opioid agonists

slide87

Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL.

  • In a randomized, double-blind clinical trial, we evaluated the impact of three medications on the signs and symptoms of withdrawal and on the pain severity in heroin-dependent HIV-infected patients (N=55) hospitalized for medical reasons on an inpatient AIDS service. Patients received a 3-day pharmacologic taper with intramuscular buprenorphine (n=21), oral clonidine (n=16), or oral methadone (n=18), followed by a clonidine transdermal patch on the fourth day. Observed and self-reported measures of opioid withdrawal and pain were taken 1-3 times daily for up to 4 days. Opiate administration used as medically indicated for pain was also recorded. Observer- and subject-rated opiate withdrawal scores decreased significantly following the first dose of medication and overall during treatment. Among all 55 subjects, self-reported and observer-reported pain decreased after treatment (on average observer-rated opioid withdrawal scale (OOWS) scores declined 5.6 units and short opioid withdrawal scale (SOWS) declined 4.8 units, P<0.001, for both) with no indication of increased pain during medicati
  • taper.
  • There were no significant differences of pain decline and other measures of withdrawal between the three treatment groups. During the intervention period, supplemental opiates were administered as medically indicated for pain to 45% of the patients; only 34% of men versus 62% of women received morphine (P<0.05). These findings suggest buprenorphine, clonidine, and methadone regimens each decrease opioid withdrawal in medically ill HIV-infected patients.
other addiction meds
Other Addiction Meds
  • Relapse prevention…Alcohol
    • Naltrexone…opiate system
    • Acamprosate…GABA system??......... just released and being evaluated in large current studies
acamprosate relapse rates
ACAMPROSATE RELAPSE RATES

% of Abstinent Patients

slide91

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.Carmen B, Angeles M, Ana M, Maria AJ.Findings Thirty-three studies met the inclusion criteria.

  • Acamprosate was associated with a significant improvement in abstinence rate [odds ratio (OR): 1.88 (1.57, 2.25), P < 0.001] and days of cumulative abstinence [WMD: 26.55 (17.56, 36.54].
  • Short-term administration of naltrexone reduced the relapse rate significantly [OR: 0.62 (0.52, 0.75), P < 0.001], but was not associated with a significant modification in the abstinence rate [OR: 1.26 (0.97,1.64), P = 0.08].
  • There were insufficient data to ascertain naltrexone\'s efficacy over more prolonged periods. Acamprosate had a good safety pattern and was associated with a significant improvement in treatment compliance [OR: 1.29 (1.13,1.47), P < 0.001]. Naltrexone\'s side effects were more numerous, yet the drug was nevertheless tolerated acceptably without being associated with a lower adherence to treatment (OR: 0.94 (0.80, 1.1), P = 0.5). However, overall compliance was relatively low with both medications.
medications in patients with addictions potential problems
Medications in Patients with Addictions….potential problems
  • Can reinforce addiction denial if Alc/Drg intervention is not integrated and supported…esp by the prescriber..
  • Can be expensive, cause side effects, could be used in overdose.
  • Encumber the pt with seeing MD, or mental health system, cost, convenience etc….ie make sure they are really necessary.
  • Active participation in recovery can be both antidep and antianx…but if serious psych problems continue, or disrupt recovery, meds should be considered
  • For more serious problems such as psychosis and mania, immediate use of medications is indicated
sleep in recovering alc addicts
Sleep in recovering Alc/Addicts
  • Abnormal for weeks/months in most
  • Is this “normal toxicity” and to be tolerated
  • Poor sleep associated with relapse, anx, dep, PTSD, and PROTRACTED WITHDRAWAL
medications for sleep in recovering addicts alcoholics
Medications for sleep in recovering addicts/alcoholics
  • Treat the comorbid disorder causing the sleep problem….ie dep/anx etc, with an antidepressant
  • And/or protracted withdrawal…..with anticonvulsants ( for one to several months)
  • Prazosin for PTSD nightmares
  • Anti histamines, trazedone, remeron as non-specific aids
  • If using BZP’s, oxazepam and librium
anticonvulsants95
Anticonvulsants
  • Role in alc withdrawal acute and/or protracted
  • Role in bipolar, esp rapid cycle
  • Role in early antipsychotic augmentation
  • Great for ongoing sleep problems... Is this protracted withdrawal?
  • Is there a role in craving/relapse prevention?
  • Is there a role for PRN use in agitated Dual pts, such as 500 mg valproate, 600 mg gabapentin etc??
anticonvulsants in alcohol withdrawal
Anticonvulsants in alcohol withdrawal
  • Good evidence for carbamazepine, valproate and growing for gabapentin and topiramate
  • May even be superior in terms of safety, ability for take home doses and in some studies, even anxiety/agitation
  • Have been shown effective in high dose BZP dependence
ad